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Summary A fluorescent probe has been employed to study the status of a tumour associated protease,
guanidinobenzoatase, in frozen sections of human tumours obtained from the head and neck regions. The
results indicate that in vivo a naturally occurring inhibitor of guanidinobenzoatase effectively controls the
activity of this enzyme on the majority of cells in a tumour mass. This inhibitor can be artificially displaced
by formaldehyde treatment of the frozen sections and this treatment reveals the extent of latent enzyme in the
section. In the frozen sections it was noticed that at the advancing edges of the tumour mass, the tumour cells
possessed uninhibited guanidinobenzoatase, an enzyme known to degrade the link peptide between cells and
fibronectin. It was shown that a synthetic inhibitor of guanidinobenzoatase selectively inhibited the
guanidinobenzoatase of the tumour cells at the advancing edge of the tumour mass. It is suggested that the
guanidinobenzoatase on cells at the leading edge of the tumour mass plays an important role in the invasion
of adjacent host tissue. This synthetic inhibitor of guanidinobenzoatase has no inhibitory action on other
trypsin-like enzymes and might therefore be of value in limiting the growth of the tumour mass in vivo.
Guanidinobenzoatase is a trypsin-like protease associated
with tumour cells (Steven et al., 1985) which may be assayed
in solution by the cleavage of methylumbelliferone from the
fluorogenic substrate 4-methylumbelliferyl-p-guanidinoben-
zoate (Steven & Al-Ahmad, 1983). This protease has been
shown to cleave the tetrapeptide GlyArgGlyAsp (Steven et
al., 1986) which is thought to link cell surfaces to fibronectin
(Pierschbacher & Ruoslahti, 1984). Guanidinobenzoatase is
competitively inhibited by 9-aminoacridine (Steven et al.,
1985), and this observation was used to locate tumour cells
containing guanidinobenzoatase by fluorescent microscopy
of formaldehyde fixed wax embedded sections. It was later
established that most host tissues contained extractable
proteins which were non-competitive inhibitors of guanidino-
benzoatase in solution (Steven et al., 1988a). These protein
inhibitors prevented the binding of 9-aminoacridine to the
protease of most tumour cells in fresh frozen sections
(Steven et al., 1988b), whilst some tumour cells possessed
uninhibited enzyme in these frozen sections. In the present
paper we have studied those tumour cells in frozen sections
which possess uninhibited guanidinobenzoatase. When
treated with 9-aminoacridine and examined by fluorescent
microscopy these uninhibited cells exhibit cytoplasmic and
cell surface yellow fluorescence; whilst other morphologically
similar tumour cells with fully inhibited guanidinobenzoatase
appear to be non-fluorescent with blue-green cytoplasm and
cell surfaces. Those tumour cells which possess uninhibited
guanidinobenzoatase were located at the advancing edge of
the tumour mass or were detected as small groups of
individual tumour cells outside the main tumour mass. This
paper is concerned with the inhibition of the guanidinoben-
zoatase on these cells at the advancing edge of the tumour
mass, since these can be more easily located than single cells
in sequential sections. The role of host tissue protein inhibi-
tors in the control of cell migration will be discussed.
BZAR [bis-(N-benzyloxycarbonyl-L-argininamido)-Rhoda-
mine] was first described by Leytus et al. (1983). BZAR
inhibits guanidinobenzoatase in solution and on the surface
of tumour cells (Steven et al., 1988), but is cleaved by other
trypsin-like enzymes (Leytus et al., 1983). As both BZAR
and 9-aminoacridine bind to the active centre of guanidino-
benzoatase we used these inhibitors, one after the other, on
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frozen sections of tumour tissue to demonstrate the selective
binding of BZAR to cells containing active guanidinoben-
zoatase as shown by those cells' subsequent inability to bind
9-aminoacridine. The possible significance of BZAR as an
inhibitor of guanidinobenzoatase is presented in the context
of the control of tumour cell migration.
Materials and methods
9-Aminoacridine was purchased from Sigma Chemical
Company, St Louis, MO, USA. A stock aqueous solution,
10-3 M, of 9-aminoacridine was used for fluorescent staining.
We employed 1O6M BZAR dissolved in isotonic saline for
the inhibition of cell bound guanidinobenzoatase. Frozen
sections of human tumours taken from the head and neck
region were kindly provided by the Pathology Department of
the Justus-Liebig University, Giessen, West Germany. In all,
over 500 frozen sections were provided from 55 subjects;
these sections contained normal tissue as well as tumour
cells, and the fluorescent examination was carried out in
total ignorance of the pathological analysis previously
carried out by conventional staining with haematoxylin-
eosin. In this study the fluorescent analyses were carried out
by F.S.S. (with no training in histology or pathology) so that
analysis was based purely on the fluorescent appearance of
the stained sections. Frozen sections from each tissue were
mounted on 3" x 1" glass microscope slides at 22°C and
subjected to four different protocols:
1. Slides were fixed in 10% formaldehyde in isotonic
saline (formalin) for 2h prior to conventional haema-
toxylin and eosin staining. These slides were examined
by a pathologist and the results later compared with the
information obtained from fluorescent staining.
2. Frozen sections were fixed in formalin for 18 h and
stained with 9-aminoacridine (10-3 M) for 2min
followed by washing in isotonic saline for either 6min
(Steven et al., 1985) or for 1 min. Although the same
type of staining was observed with 6 min or 1 min wash,
the intensity of staining was greater after 1 min due to
less solvent extraction of the bound probe. The 1 min
procedure was essential for the colour photography of
fresh frozen sections (see (3) below) and therefore we
photographed sections after the 1 min wash on all
occasions, so that valid comparisons could be made.
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3. Fresh frozen sections were stained for 2 min with 9-
aminoacridine (10-3M) and washed for 1 min. These
sections had never been exposed to formalin.
4. Fresh frozen sections were placed in an isotonic NaCI
solution containing 10-6m BZAR at room temperature
for 2 h. The sections were then treated as (3) above.
These 9-aminoacridine treated sections were then exam-
ined by fluorescent microscopy (Steven et al., 1985), cells
exhibiting yellow fluorescence on the surface and in the
cytoplasm contained guanidinobenzoatase capable of binding
and stacking the fluorescent probe 9-aminoacridine. Photo-
graphy was carried out with an Olympus OM2N camera
with a yellow interference filter and Kodak colour film,
ASA 400.
Results and discussion
In this study we are primarily concerned with the enzymic
activity of those cells at the advancing edge of the tumour
masses seen in our sections. It is important however to
report first of all on the whole tumour mass and surround-
ing cells when all the inhibitor present in frozen sections had
been removed by formaldehyde treatment (procedure 2 in
Materials and methods). The displacement of protein inhibi-
tors by formaldehyde and the isolation of such inhibitors on
affinity supports has been reported earlier (Steven et al.,
1986). In formalin fixed frozen sections all the cells within
the tumour mass bound 9-aminoacridine (Figure 1, patient
HJ illustrates the typical staining of these cells). The nuclei
of the tumour cells were not stained and this was also typical
of individual tumour cells outside the tumour mass, however
the cytoplasm and cell surfaces fluoresced yellow. These
tumour cells clearly possessed guanidinobenzoatase which
bound 9-aminoacridine after formaldehyde fixation. It is
worth pointing out at this stage that examination of the
formaldehyde fixed sections resulted in the slides from 50
patients being predicted as bearing tumour whilst 5 were
considered to be non-tumorous controls. These predictions
were later confirmed by the pathologist; agreement being
absolute for every section.
In order to present evidence on the enzymic activity of the
cells at the advancing edge of the tumour mass, the data in
Figures 2-8 are all taken from the same patient, WR. In
Figure 2 the formaldehyde fixed section of WR shows that
the cells within the tumour mass bind 9-aminoacridine
equally as well as those at the edge of the tumour mass
where inhibitors have first been displaced by formaldehyde
treatment. On the other hand when frozen sections of WR
were stained with 9-aminoacridine directly, the majority of
the tumour cells in the tumour mass did not bind 9-
aminoacridine and appeared blue-green (Figure 3). These
cells possess guanidinobenzoatase which could be stained
after formaldehyde treatment (Figure 2). It is concluded that
the cells in the frozen sections and in vivo contained inhibited
guanidinobenzoatase. It was observed that the tumour cells
at the advancing edge of the tumour mass in frozen sections
of WR did bind 9-aminoacridine (Figures 4-6) whilst
adjacent tumour cells did not do so. Figure 8 shows the
corresponding haematoxylin-eosin staining of section WR. It
is evident that positive fluorescence (Figures 4-6) represents
the invasion front of the squamous cell carcinoma, indicated
by the arrows. We concentrated our attention on these cells
at the advancing edge, since they appeared to be in close
contact with the normal tissue of the host. The photographs
in Figures 4-6 should be compared to Figure 3 in which all
the cell-bound enzyme is inhibited and Figure 2 in which all
the cell bound-enzyme is exposed for binding 9-aminoacri-
dine by prior removal of inhibitors with formaldehyde.
These results obtained with sections from WR were typical
of those obtained from sections with obvious clumps of
tumour cells or tumour masses similar to those shown here.
We interpret the evidence of Figures 3-6 to indicate that
only the tumour cells in contact with the host tissue possess
uninhibited guanidinobenzoatase which may be located with
9-aminoacridine. The tumour cells in the interior of the
tumour mass do not possess active guanidinobenzoatase in
vivo. It could be argued that guanidinobenzoatase diffused
out of the cells in the frozen sections, thereby giving negative
observations after 9-aminoacridine staining of unfixed
sections. The evidence presented in Figures 3-6 indicate that
the guanidinobenzoatase did not diffuse out of those tumour
cells at the advancing edge of the tumour mass. The fact that
formalin treatment enabled all the tumour cells to bind 9-
aminoacridine (Figures 1, 2 and 7) indicates that latent
guanidinobenzoatase was present in the frozen sections, even
though the cells failed to bind 9-aminoacridine prior to
formalin treatment. The evidence suggests that the enzyme
remains in the cells; we believe it to be membrane bound.
Unpublished data (FS) from studies on whole formalin-fixed
tumour cells demonstrated that guanidinobenzoatase was
located on the cell surface and could be reversibly inhibited
by protein inhibitors in a similar manner to that described
above. We know that this protease can cleave the link
peptide of fibronectin and it is postulated that this enzyme
plays a role in both tissue invasion by tumour cells and cell
migration by such cells as infiltrating lymphocytes and
macrophages. It would seem from the data in Figures 3-6
that the cells within the tumour mass do not need active
guanidinobenzoatase. Two possibilities can be considered to
further characterise these cells within the tumour mass; either
the cells lack enzyme or the cells possess totally inhibited
enzyme. Treatment of the same slide used to provide the
data in Figures 3-6 with formaldehyde followed by 9-
aminoacridine staining (Figure 7) revealed latent or inhibited
enzyme associated with the cells within the tumour mass. It
should be noted that the tumour cells at the advancing edge
of the tumour mass were morphologically identical to those
in the centre of the tumour mass when examined by
conventional methods. It would seem that fluorescent probes
can offer valuable information on the activity of one import-
ant tumour associated enzyme in frozen sections which is not
readily made available by conventional histochemical tech-
niques. The processing of these unfixed frozen sections takes
4 minutes from the receipt of the slide to the examination by
fluorescent microscopy. It is therefore hoped that this fluor-
escent technique may be of value to surgeons.
The observation that single tumour cells, individual infil-
trating lymphocytes and macrophages also possessed uninhi-
bited guanidinobenzoatase in frozen sections might imply
that those cells at the advancing edge of the tumour mass
needed this protease for invasion of the host tissue. Selective
inhibition of uninhibited guanidinobenzoatase on cells at the
advancing edge of a tumour mass might have potential
value. Kinetic studies with soluble guanidinobenzoatase in
the presence of BZAR indicated that this agent is an
effective inhibitor of guanidinobenzoatase; (these data have
been reported in detail, see Figures 1-5 in Steven et al.,
1988). BZAR was found to be a non-competitive irreversible
inhibitor of guanidinobenzoatase in this chemical study
although it was shown to be a good substrate of trypsin-like
enzymes (Leytus et al., 1983). Treatment of frozen sections
with 10-6M BZAR resulted in the binding of BZAR to
tumour cells with active guanidinobenzoatase, this bound
BZAR could be directly observed by fluorescent microscopy
employing appropriate wavelengths for rhodamine (data not
presented here). Treatment of frozen sections with BZAR
(106M) dissolved in isotonic saline, followed by 9-aminoac-
ridine staining completely abolished the ability of the tumour
cells to bind the fluorescent probe. The appearance of the
cells was similar to that shown in Figure 3. Clearly the
BZAR inhibited cell-bound guanidinobenzoatase. If the
BZAR treated sections were then treated with formaldehyde
and restained, those cells within the tumour mass on which
the enzyme had been protected by the inhibitor were now
capable of binding the 9-aminoacridine (data similar to
Figure 7). From the data presented above it is clear thatTUMOUR-ASSOCIATED PROTEASES 59
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Figure 1 Frozen section (HJ) treated with formaldehyde and then stained with 9-aminoacridine. The inhibitors of guanidino-
benzoatase were displaced with formaldehyde and all the cells now bind the fluorescent probe. (x 250)
Figure 2 Frozen section (WR) treated as in Figure 1 to remove inhibitors and stained with 9-aminoacridine. (x 250)
Figure 3 Frozen section (WR) stained with 9-aminoacridine. The tumour cells within the mass of the tumour do not stain since
they still retain inhibitor on their guanidinobenzoatase. ( x250)
Figure 4 Frozen section (WR) stained with 9-aminoacridine. The tumour cells at the advancing edge of the tumour mass
fluoresced with the probe for guanidinobenzoatase, these cells possess uninhibited enzyme. The cells in the interior of the tumour
mass possess inhibited enzyme. ( x 250)
Figures 5 and 6 Frozen section (WR) stained with 9-aminoacridine. The tumour cells at the advancing edge of the tumour mass
fluoresced with the probe for guanidinobenzoatase, these cells possess uninhibited enzyme. The cells in the interior of the tumour
mass possess inhibited enzyme. (x 250)
Figure 7 Frozen section (WR) initially stained with 9-aminoacridine (Figures 3-7) and then treated with formaldehyde and
restained. The inhibition observed in the frozen section (Figures 3-6) has now been destroyed by formaldehyde treatment with
consequent binding of 9-aminoacridine to all the cells of the tumour mass. ( x 250)
Figure 8 Haematoxylin-eosin staining of section (WR). Squamous cell carcinoma invading stroma. Arrows indicate the invasion
front; note the increased cellularity. ( x 500)
BZAR did not displace any inhibitor from guanidinobenzo-
atase but merely reacted with the uninhibited enzyme on
'active' cells at the edge of the tumour mass. We have
previously shown that 9-aminoacridine is also an inhibitor of
the free and cell-bound guanidinobenzoatase (Steven et al.,
1985). We considered the effect of BZAR on tumour cells
previously treated with 9-aminoacridine, since both these
molecules are attracted to the same active centre. Pretreat-
ment of frozen sections with 9-aminoacridine, followed by
BZAR then followed by a second 9-aminoacridine staining
resulted in the same staining of the tumour cells at the
advancing edge of the tumour mass (data similar to Figures
3-6). The BZAR does not displace stacked 9-aminoacridine
already in the active centre but pretreatment with BZAR
prevents 9-aminoacridine being bound. Clearly both BZAR
and 9-aminoacridine have an affinity for the same locus, in
this case, the active centre of uninhibited cell-bound
guanidinobenzoatase.
In the present situation we have one enzyme (the protease)
and three classes of inhibitor, (a) the host tissue protein
inhibitor, (b) our fluorescent probe 9-aminoacridine, and (c)
the synthetic arginine derivative, BZAR.
The fluorescence of bound 9-aminoacridine allows us to
follow the enzymic activity of cells in frozen sections in the
presence of the two other inhibitors and decide how these
two inhibitors have reacted with the enzyme; either alone or
in competition with each other. If guanidinobenzoatase is
indeed significant for tumour cell advance, then BZAR also
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may have significance as an agent for the possible control of
tumour cell advance. One advantage of BZAR is that this
compound is unlikely to inhibit other trypsin-like enzymes
since these are capable of degrading BZAR (Leytus et al.,
1983). The low molecular weight of BZAR (638) and high
solubility in aqueous media would ensure that this com-
pound would have easy access to guanidinobenzoatase on
the surface of tumour of cells in vivo. For the same reasons
both BZAR and 9-aminoacridine (molecular weight 230)
have no difficulty in diffusing through frozen sections and
even resin embedded sections (Steven et al., 1986). These
qualities make low molecular weight probes superior to
fluorescent antibodies in this type of work.
This study was supported by the Imperial Cancer Research Fund.
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